Company news
Erasca, Inc. news in 2021
Erasca, Inc.'s news releases, calls and decks from 2021, newest first.
Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial
December 16, 2021
Erasca Added to the Nasdaq Biotechnology Index
December 13, 2021
Erasca to Present at the Evercore ISI 4th Annual HealthCONx Conference
November 15, 2021
Erasca Reports Third Quarter 2021 Financial Results and Business Updates
November 9, 2021
Erasca Announces Presentation of Preclinical Data on ERAS-801, a CNS-Penetrant EGFR Inhibitor with Broad Activity against Oncogenic EGFR Alterations, at AACR Conference on Brain Cancer
October 24, 2021
Erasca is Named One of Fierce Biotech’s “Fierce 15” Biotechnology Companies of 2021
September 26, 2021
Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
September 21, 2021
Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
September 8, 2021
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Encorafenib Combination
September 7, 2021
Erasca to Participate in the Morgan Stanley 19th Annual Global Healthcare Virtual Conference
September 1, 2021
Erasca Reports Second Quarter 2021 Financial Results and Business Updates
August 25, 2021
Erasca Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 19, 2021
Erasca Announces Pricing of Upsized Initial Public Offering
July 14, 2021
Decks in 2021
- Technical Presentation (October 2021)
Technical · 28 slides · Oct 25, 2021